Barinthus Biotherapeutics PLC Sponsored ADR $BRNS Shares Sold by Gilead Sciences Inc.

Key Points

• Gilead Sciences Inc. reduced its stake in Barinthus Biotherapeutics by 40.4%, now holding 369,855 shares, which represents about 0.0% of its overall portfolio.
• Barinthus Biotherapeutics reported an EPS of ($0.52) for the last quarter, missing consensus estimates, reflecting ongoing challenges as it develops immunotherapeutic candidates.
• The company's stock opened at $1.26 with a 1-year high of $2.92 and a low of $0.64, indicating volatility in its market performance.

Gilead Sciences Inc. lessened its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) by 40.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 369,855 shares of the company's stock after selling 250,496 shares during the quarter. Barinthus Biotherapeutics accounts for about 0.0% of Gilead Sciences Inc.'s portfolio, making the stock its 14th largest holding. Gilead Sciences Inc. owned about 0.92% of Barinthus Biotherapeutics worth $360,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, HighTower Advisors LLC acquired a new position in Barinthus Biotherapeutics in the first quarter valued at approximately $36,000. Institutional investors and hedge funds own 25.20% of the company's stock.

Barinthus Biotherapeutics Trading Up 3.4%

Barinthus Biotherapeutics stock traded up $0.0380 during mid-day trading on Wednesday, hitting $1.14. The company had a trading volume of 11,513 shares, compared to its average volume of 515,476. The company has a market capitalization of $45.99 million, a price-to-earnings ratio of -0.66 and a beta of -0.73. The company's fifty day moving average is $1.20 and its 200-day moving average is $1.02. Barinthus Biotherapeutics PLC Sponsored ADR has a 12-month low of $0.64 and a 12-month high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.23). As a group, sell-side analysts expect that Barinthus Biotherapeutics PLC Sponsored ADR will post -1.38 EPS for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.